SCHEMBL6790723

SCHEMBL6790723

O=C1Cn2c3c(c4cccc(c42)N1)CCN(C(=O)O)CC3

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.40
KMT2A Q03164 3/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 3/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
KDM4E B2RXH2 1/20 0.37
SHMT2 P34897 1/20 0.36
CASP3 P42574 1/20 0.36
CASP2 P42575 1/20 0.36
BRD4 O60885 1/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
RAB9A P51151 1/20 0.36
MTHFD2 P13995 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26134436 0.93 PTGDR2 (0.40) HTTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL5510488 0.84 CRBN (0.45) BRD4GSK3BMAPK1PARP1
SCHEMBL25342379 0.82 EP300 (0.37) HTTSHMT2CASP3CASP2PTGDR2
SCHEMBL5510632 0.80 SMN1; SMN2 (0.43) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL12456829 0.80 HTR6 (0.55) ALDH1A1KDM4EGSK3AGSK3BGAA
SCHEMBL7030588 0.73 MCL1 (0.52) HTTKMT2AMEN1ALDH1A1POLB
SCHEMBL5507331 0.72 CRBN (0.52) BRD4GSK3BMAPK1PARP1
SCHEMBL5511782 0.70 DRD2 (0.53) KMT2AMEN1POLBMAPTKDM4E
SCHEMBL6851523 0.70 HTR2A (0.39) PTGDR2HTR1AADRA2AADRA2BADRA2C
SCHEMBL29984269 0.69 PTGDR2 (0.43) PTGDR2MTHFD2HTR1AADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040220178-A1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220178-A1 Substituted heterocycle fused gamma-carbolines HCRTR1, HTR2C, OPRK1 HTT 637/4885KMT2A 323/4885MEN1 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.